"Cancer services at Rush are ranked among the best in the country by U.S. News & World Report."

During the past decade, Rush Cancer Institute at Rush University Medical Center conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 1 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Rush Cancer Institute at Rush University Medical Center" #1 sponsor was "Genitope Corporation" with 2 trials, followed by "NSABP Foundation Inc" with 2 trials sponsored, "Northwestern University" with 2 trials sponsored, "American College of Radiology Imaging Network" with 1 trials sponsored and "CTI BioPharma" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Rush Cancer Institute at Rush University Medical Center" #1 collaborator was "National Cancer Institute (NCI)" with 6 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator and "Radiation Therapy Oncology Group" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Rush Cancer Institute at Rush University Medical Center" are "Lung Cancer" (4 trials), "Lymphoma" (3 trials), "Breast Cancer" (2 trials), "Brain and Central Nervous System Tumors" (1 trials) and "Head and Neck Cancer" (1 trials). Many other conditions were trialed in "Rush Cancer Institute at Rush University Medical Center" in a lesser frequency.

Most popular intervention types in "Rush Cancer Institute at Rush University Medical Center" are "Drug" (8 trials), "Biological" (6 trials), "Procedure" (2 trials), "Genetic" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "sargramostim" (4 trials), "autologous immunoglobulin idiotype-KLH conjugate vaccine" (3 trials), "carboplatin" (3 trials), "cyclophosphamide" (2 trials) and "paclitaxel" (2 trials). Other intervention names were less common.

The vast majority of trials in "Rush Cancer Institute at Rush University Medical Center" are 8 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Rush Cancer Institute at Rush University Medical Center". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Rush Cancer Institute at Rush University Medical Center, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Rush Cancer Institute at Rush University Medical Center, 0 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".